{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-36MUEQAU/d3458b48-8011-4c4b-826d-138a6500d720/PDF","dcterms:extent":"1192 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-36MUEQAU/bb80eb5f-0586-47c1-9056-d9d4e6f68540/TEXT","dcterms:extent":"42 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-36MUEQAU","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2024","dc:creator":["Kirbus, Klemen","Kocbek, Petra","Žiberna, Lovro"],"dc:format":[{"@xml:lang":"sl","#text":"številka:5"},{"@xml:lang":"sl","#text":"letnik:75"},{"@xml:lang":"sl","#text":"str. 357-366"}],"dc:identifier":["ISSN:0014-8229","COBISSID_HOST:220980739","URN:URN:NBN:SI:doc-36MUEQAU"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"Dostavni sistemi"},{"@xml:lang":"en","#text":"drug delivery systems"},{"@xml:lang":"en","#text":"in vitro characterisation"},{"@xml:lang":"sl","#text":"nanodelci"},{"@xml:lang":"en","#text":"nanoparticles"},{"@xml:lang":"sl","#text":"organ na čipu"},{"@xml:lang":"en","#text":"organ-on-achip"},{"@xml:lang":"sl","#text":"tumor na čipu"},{"@xml:lang":"en","#text":"tumor-on-a-chip"},{"@xml:lang":"sl","#text":"vrednotenje in vitro"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Organi na čipu in njihov potencial pri vrednotenju nanodostavnih sistemov| Organs-on-a-chip and their potential in characterization of nanodelivery systemses|"},"dc:description":[{"@xml:lang":"sl","#text":"The advancement of pharmaceutical nanotechnology is accompanied by the need to evaluate nanodelivery systems, especially nanoparticles, on models that mimic in vivo conditions. This is enabled by organs-on-a-chip, which represent cells cultured in a three-dimensional extracellular matrix with relevant fluidics. This setup offers a more biorelevant environment than traditional two-dimensional static cell cultures due to the biomechanical forces that influence gene expression and cell phenotype. Most research in the field is focused on establishing complex disease models or in vitro drug evaluation. Moreover, their use is expanding to include the evaluation of nanodelivery systems and nanomedicines. These chips are primarily used to study nanoparticle transport across biological barriers and the efficacy of nanodelivery systems against tumors in vitro. Continued development is expected to expand the use of organs-on-a-chip from primarily research labs to broader applications within the pharmaceutical industry"},{"@xml:lang":"sl","#text":"Napredek farmacevtske nanotehnologije spremlja potreba po vrednotenju razvitih nanodostavnih sistemov in nanozdravil na modelih, ki posnemajo pogoje in vivo. To omogočajo organi na čipu, ki temeljijo na gojenju različnih vrst celic v tridimenzionalnem ogrodju v pretočnem sistemu. Prednost te tehnologije je možnost gojenja celic v bolj biorelevantnem okolju, kot so pogoji v klasičnih statičnih dvodimenzionalnih celičnih kulturah, in sicer v prisotnosti biomehanskih sil, ki delujejo na celice v čipih, kar vodi v spremenjeno izražanje genov in spremenjen fenotip celic. Organi na čipu se v raziskavah največ uporabljajo z namenom postavljanja modelov bolezni in za vrednotenje zdravilnih učinkovin in vitro. Z razvojem tehnologije se njihova uporaba širi tudi na vrednotenje nanodostavnih sistemov in nanozdravil, predvsem za vrednotenje njihovega prehajanja skozi biološke bariere ter proučevanje njihovega protitumornega delovanja in vitro. Z nadaljnjim razvojem lahko pričakujemo prenos tehnologije organov na čipu iz raziskovalnih laboratorijev v širšo uporabo v farmacevtski industriji"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-36MUEQAU","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-36MUEQAU"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-36MUEQAU/d3458b48-8011-4c4b-826d-138a6500d720/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-36MUEQAU/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-36MUEQAU"}}}}